The manufacturer of "EpiVakKorona" demanded ₽260 million for low-quality protein

The Novosibirsk company JSC Vector-BiAlgam, which produces vaccines against the CORONAVIRUS EpiVacKorona, filed a lawsuit against the pharmaceutical company Geropharm with a request to recover 259.6 million rubles to the Arbitration COURT of the Novosibirsk Region. Information about this is contained in the case card.

The court accepted the claim, but left it without progress until August 25 inclusive: the plaintiff did not attach documents confirming that the plaintiff complied with the claim or other pre-trial procedure.

According to Kommersant, since the end of 2020, Geropharm has been producing a carrier protein with which peptides are combined. It is necessary for the production of a peptide vaccine. In June last year, Vector-BiAlgam ordered a carrier protein from Geropharm for the production of EpiVacCorona.

In March of this year, Geropharm filed a lawsuit with the Arbitration Court of St. Petersburg and the Leningrad Region against Vector-BiAlgam JSC due to a debt in payment for goods in the amount of 203 million rubles. Vector-BiAlgam indicated that the company had partially delivered a low-quality carrier protein. On July 15, the court decided to recover 173.1 million rubles from Vector-BiAlgam. debt for the supply of protein and 18.2 million rubles. penalties.

Geropharm believes that the counterclaim of Vector-BiAlgam JSC is aimed at delaying the process of recovering funds based on a court decision.

“As for the quality of the supplied raw materials, it should be noted that within the framework of the project for the production of a carrier protein for the vaccine, a responsible and complex procedure was carried out for accepting the quality of raw materials at the site of Vector-BiAlgam JSC,” Geropharm’s press service told RBC Novosibirsk .

This is due to the fact that during the transportation of protein there may be risks of quality loss for various reasons. We are talking about compliance with the temperature regime, stability during shaking and other reasons.

Is this normal or should I call an ambulance? Pro Instructions How Companies Cut Payroll Spending:

“Such a responsible approach allows us to identify possible changes in the quality of raw materials at the stage of acceptance,” the company noted.

All suspected raw materials were quarantined and destroyed in order to eliminate the risk of low-quality drug getting into circulation. In exchange, Vector-BiAlgam was supplied with new raw materials, the quality of which was tested and accepted.

RBC Novosibirsk sent a request to Vector-BiAlgam.

JSC "Vector-BiAlgam" was founded in 1996 on the basis of the State Scientific Center of Virology and Biotechnology "Vector" in the science city of Koltsovo. The company develops and manufactures vaccines and probiotic products.

According to the Kontur.Focus service, the CEO and owner of Vector-BiAlgam JSC is Leonid Nikulin. The company is associated with the following trademarks: Narilak, Narilak-Forte-V, Nariflor, Bifid, Probiliosis and Immunolysis. At the end of 2021, revenue amounted to 2.4 billion rubles, net profit - 534.8 million rubles. The company employs 310 people.

In March 2021, on the basis of Vector-BiAlgam, the production of the covid-19 vaccine EpiVacCorona, which was developed by the specialists of the Vector Center, began.

Geropharm LLC was founded in 2000. General DIRECTOR - Petr Rodionov. He also owns a little more than a quarter of the authorized capital of the enterprise. At the end of 2021, the company's revenue is 11.5 billion rubles, net profit is 3.1 billion rubles.